TY - JOUR
T1 - Hybrid Milk Extracellular Vesicles as Potential Systems for Oral Delivery of siRNA
AU - Zhang, Yunyue
AU - Luo, Charlie
AU - Belaid, Mona
AU - Thanou, Maya
AU - Vllasaliu, Driton
N1 - Funding Information:
This work was supported by the King's‐China Scholarship Council PhD Scholarship Programme.
Funding Information:
This work was supported by the King's-China Scholarship Council PhD Scholarship Programme.
Publisher Copyright:
© 2024 The Authors. Advanced Therapeutics published by Wiley-VCH GmbH.
PY - 2024/3
Y1 - 2024/3
N2 - Oral administration of RNA is currently not possible and current approaches for RNA delivery by injection are not suitable for the oral route. In this work, novel bioinspired nanoparticles for oral delivery of RNA therapies are reported. Specifically, the fabrication of hybrid nanovesicles (“hybridosomes”) based on bovine milk extracellular vesicles (mEVs) and liposomes is reported. Hybridosomes are fabricated using two related methods based on freeze-thawing of mEVs and cationic liposomes. The systems are 180–230 nm and demonstrated efficient loading of small interfering (siRNA) cargo. Hybridosomes exhibit significantly lower cytotoxicity in intestinal Caco-2 cells compared to cationic liposomes and superior stability in a fed-state simulated intestinal fluid compared to liposomes. Furthermore, these systems significantly increase the transport of siRNA across in vitro intestinal model. Finally, hybridosomes loaded with siRNA successfully induce transfection in J774A.1 macrophages. Overall, the results show that the hybrid systems fabricated here offer potential for oral delivery of RNA therapeutics.
AB - Oral administration of RNA is currently not possible and current approaches for RNA delivery by injection are not suitable for the oral route. In this work, novel bioinspired nanoparticles for oral delivery of RNA therapies are reported. Specifically, the fabrication of hybrid nanovesicles (“hybridosomes”) based on bovine milk extracellular vesicles (mEVs) and liposomes is reported. Hybridosomes are fabricated using two related methods based on freeze-thawing of mEVs and cationic liposomes. The systems are 180–230 nm and demonstrated efficient loading of small interfering (siRNA) cargo. Hybridosomes exhibit significantly lower cytotoxicity in intestinal Caco-2 cells compared to cationic liposomes and superior stability in a fed-state simulated intestinal fluid compared to liposomes. Furthermore, these systems significantly increase the transport of siRNA across in vitro intestinal model. Finally, hybridosomes loaded with siRNA successfully induce transfection in J774A.1 macrophages. Overall, the results show that the hybrid systems fabricated here offer potential for oral delivery of RNA therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85182474407&partnerID=8YFLogxK
U2 - 10.1002/adtp.202300335
DO - 10.1002/adtp.202300335
M3 - Article
SN - 2366-3987
VL - 7
JO - Advanced Therapeutics
JF - Advanced Therapeutics
IS - 3
M1 - 2300335
ER -